Whole-Brain N-Acetylaspartate Concentration: Correlation with T2-Weighted Lesion Volume and Expanded Disability Status Scale Score in Cases of Relapsing-Remitting Multiple Sclerosis

References

1. ↵
   Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neuro Sci 1979;41:81–91
2. ↵
   McFarland H. The lesion in multiple sclerosis: clinical, pathological, and magnetic resonance imaging considerations. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):S26–S30
3. ↵
   Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393–399

   Abstract/FREE Full Text
4. ↵
   Barkhof F. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). Mult Scler 1999;5:283–286

   Abstract/FREE Full Text
5. ↵
   Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45:255–260

   Abstract/FREE Full Text
6. ↵
   Miki Y, Grossman RI, Udupa JK, et al. Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images: lack of correlation between changes in T2 lesion volume and clinical findings. Radiology 1999;213:395–399

   CrossRefPubMedWeb of Science
7. Pike GB, de Stefano N, Narayanan S, Francis GS, Antel JP, Arnold DL. Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. AJNR Am J Neuroradiol 1999;20:829–837

   Abstract/FREE Full Text
8. ↵
   Stevenson VL, Miller DH. Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Mult Scler 1999;5:268–272

   Abstract/FREE Full Text
9. ↵
   Kauppinen RA, Williams SR. Nuclear magnetic resonance spectroscopy studies of the brain. Prog Neurobiol 1994;44:87–118

   CrossRefPubMedWeb of Science
10. ↵
    Simmons MS, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl aspartate with monoclonal antibodies. Neuroscience 1991;45:37–45

    CrossRefPubMedWeb of Science
11. ↵
    Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluations of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154–159

    PubMedWeb of Science
12. ↵
    De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901–909

    CrossRefPubMedWeb of Science
13. ↵
    Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49–58

    Abstract/FREE Full Text
14. Grossman RI, Lenkinski RE, Ramer KN, Gonzalez-Scarano F, Cohen JA. MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol 1992;13:1535–1543

    Abstract/FREE Full Text
15. ↵
    Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. [published erratum appears in Neurology 1991 Nov;41(11):1828] Neurology 1991;41:1251–1256

    Abstract/FREE Full Text
16. ↵
    Filippi M, Tortorella C, Bozzali M. Normal-appearing white matter changes in multiple sclerosis: the contribution of magnetic resonance techniques. Mult Scler 1999;5:273–282

    Abstract/FREE Full Text
17. Hiehle JF Jr, Lenkinski RE, Grossman RI, et al. Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med 1994;32:285–293

    PubMedWeb of Science
18. Tourbah A, Stievenart JL, Iba-Zizen MT, Zanoli G, Lyon-Caen O, Cabanis EA. In vivo localized proton NMR spectroscopy of normal appearing white matter in patients with multiple sclerosis. J Neuroradiol 1996;23:49–55

    PubMedWeb of Science
19. ↵
    Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121:103–113

    Abstract/FREE Full Text
20. ↵
    Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15–19

    Abstract/FREE Full Text
21. ↵
    Gonen O, Viswanathan AK, Catalaa I, Babb J, Udupa J, Grossman RI. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684–689

    PubMedWeb of Science
22. ↵
    Gonen O, Grossman RI. The accuracy of whole brain N-acetylaspartate quantification. Magn Reson Imaging 2000;18:1255–1258

    CrossRefPubMedWeb of Science
23. ↵
    Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893–901

    CrossRefPubMedWeb of Science
24. ↵
    Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bo L. Axonal transection in the lesions of multiple sclerosis. New Engl J Med 1998;85:278–285
25. ↵
    Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385–391

    CrossRefPubMedWeb of Science
26. ↵
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452

    Abstract/FREE Full Text
27. ↵
    Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–231

    CrossRefPubMedWeb of Science
28. ↵
    Udupa J, Samarasekera S. Fuzzy connectedness and object definition: theory, algorithms and applications in image segmentation. Graph Models Image Proc 1996;33:480–489
29. ↵
    Udupa JK, Wei L, Miki Y, Grossman RI. A system for the comprehensive analysis of multiple sclerosis lesion load based on MR imagery. Proc Soc Photo-Optical Instr Engineers 1997;3031:610–618
30. ↵
    Ge Y, Grossman RI, Udupa JK, et al. Longitudinal quantitative analysis of brain atrophy in relapsing-remitting and secondary-progressive multiple sclerosis. Radiology 1999;214:665–670

    PubMedWeb of Science
31. ↵
    Samarasekera S, Udupa JK, Miki Y, Wei L, Grossman RI. A new computer-assisted method for the quantification of enhancing lesions in multiple sclerosis. J Comp Assist Tomogr 1997;21:145–151

    CrossRefPubMed
32. ↵
    Fox NC, Miller DH, Thompson AJ. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI [reply]. Neurology 2000;55:1243–1243

    FREE Full Text
33. ↵
    Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999;53:1698–1704

    Abstract/FREE Full Text
34. ↵
    van Walderveen MA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282–1288

    Abstract/FREE Full Text
35. ↵
    Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991;2:131–134

    PubMedWeb of Science
36. ↵
    Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981–989

    Abstract
37. ↵
    Bhakoo KK, Pearce D. In vitro expression of N-acetyl aspartate by oligodendrocytes: implications for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 2000;74:254–262

    CrossRefPubMedWeb of Science
38. ↵
    Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998;18:601–609

    Abstract/FREE Full Text
39. ↵
    De Stefano N, Matthews PM, Narayanan S, Francis GS, Antel JP, Arnold DL. Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997;49:1138–1141

    Abstract/FREE Full Text
40. De Stefano N, Matthews PM, Fu LQ, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469–1477

    Abstract/FREE Full Text
41. ↵
    De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65–70

    CrossRefPubMedWeb of Science
42. ↵
    Suhy J, Rooney WD, Goodkin DE, et al. H-1 MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS. Mult Scler 2000;6:148–155

    Abstract/FREE Full Text
43. ↵
    Noseworthy J, Vandervoot M, Wong C, Ebers G. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in multiple sclerosis clinical trial: The Canadian Cooperation MS Study Group. Neurology 1990;40:971–975

    Abstract/FREE Full Text
44. ↵
    Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000;123:1027–1040

    Abstract/FREE Full Text
45. ↵
    Arnett PA, Higginson CI, Voss WD, Bender WI, Wurst JM, Tippin JM. Depression in multiple sclerosis: relationship to working memory capacity. Neuropsychology 1999;13:546–556

    CrossRefPubMedWeb of Science
46. ↵
    Arnett PA, Rao SM, Bernardin L, Grafman J, Yetkin FZ, Lobeck L. Relationship between frontal lobe lesions and Wisconsin Card Sorting Test performance in patients with multiple sclerosis. Neurology 1994;44:420–425

    Abstract/FREE Full Text
47. ↵
    Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment: National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244–250

    Abstract/FREE Full Text
48. ↵
    Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994;36:157–165

    CrossRefPubMedWeb of Science
49. ↵
    Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 1995;64:742–748

    PubMedWeb of Science